Holen Sie sich die Stockscreener-App
11.04
1.34%
-0.15
Handel nachbörslich:
11.04
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St
RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com
Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com
Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com
RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World
UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks
HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Morgan Stanley's Strategic Acquisition of UroGen Pharma Shares - GuruFocus.com
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - BioSpace
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
UroGen Pharma Ltd (URGN) Q3 2024 Earnings: EPS of ($0.55) and Re - GuruFocus.com
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
UroGen's JELMYTO Sales Surge 20% to $25.2M as FDA Fast-Tracks UGN-102 Review | URGN Stock News - StockTitan
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire
(URGN) Investment Analysis - Stock Traders Daily
Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
UroGen started at buy by EF Hutton, RTGel technology cited - MSN
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance
FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India
When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register
URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com
UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News
UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com UK
UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat
Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology
UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian
UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
UroGen Pharma (NASDAQ:URGN) Upgraded to "Strong-Buy" by EF Hutton Acquisition Co. I - MarketBeat
EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa
EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN
UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily
Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News
UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat
UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz
UroGen Pharma announces executive changes - Investing.com
Urogen Pharma falls on CFO appointment - XM
UroGen Pharma Announces CFO Transition and Compensation Details - TipRanks
UroGen Pharma appoints Chris Degnan as CFO - Investing.com
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):